The cancer tumor profiling market size has grown rapidly in recent years. It will grow from $14.97 billion in 2025 to $17.1 billion in 2026 at a compound annual growth rate (CAGR) of 14.3%. The growth in the historic period can be attributed to increasing utilization of tumor biopsy testing, expansion of oncology research programs, early clinical adoption of molecular stratification, growth of hospital-based profiling services, rising availability of advanced laboratory infrastructure.
The cancer tumor profiling market size is expected to see rapid growth in the next few years. It will grow to $28.27 billion in 2030 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to increasing demand for precision oncology decision-making, expansion of personalized cancer therapies, growing investments in translational research, rising adoption of advanced sequencing technologies, increasing focus on predictive oncology diagnostics. Major trends in the forecast period include increasing use of multi-omics tumor profiling, rising adoption of targeted sequencing panels, growing integration of AI-driven biomarker analysis, expansion of personalized treatment planning, enhanced focus on prognostic profiling.
The rising incidences of cancer worldwide are expected to drive the growth of the cancer and tumor profiling market in the coming years. Cancer is a disease in which certain cells in the body grow uncontrollably and spread to other parts of the body. As cancer cases increase, the demand for cancer tumor profiling also rises, as it helps doctors assess the severity of the disease. For example, in 2024, the American Cancer Society, a US-based professional organization, reported 2 million new cancer cases in the country, up from 1.9 million new cases in 2023. Thus, the growing number of cancer cases globally fuels the expansion of the cancer and tumor profiling market.
The rising incidence of stomach cancer is expected to drive the growth of the cancer and tumor profiling market in the coming years. Stomach cancer involves the uncontrolled growth and proliferation of malignant cells in the stomach lining. While gastrointestinal stromal tumors (GISTs) can also develop in the stomach, they are different from stomach cancer. When two distinct tumors merge, patients with GISTs have been observed to have a higher risk of developing additional cancers, including small bowel adenocarcinoma. Cancer and tumor profiling provides insights into cancer development in the stomach and helps guide more effective treatment. For example, according to Cancer Research UK, an independent cancer research organization, the incidence of stomach cancer in the UK is expected to decrease by 12% between 2023-2025 and 2038-2040, averaging 8 cases per 100,000 people per year. Consequently, the increasing incidence of stomach cancer is fueling the growth of the cancer and tumor profiling market.
In February 2024, AbbVie Inc. acquired US-based pharmaceutical company ImmunoGen, Inc. for an undisclosed amount. Through this acquisition, AbbVie Inc. intends to enhance its research and development capabilities, expand its product portfolio, and accelerate growth in key therapeutic areas. ImmunoGen, Inc. is a US-based biotechnology firm specializing in the development of antibody-drug conjugate therapeutics for cancer treatment.
Major companies operating in the cancer tumor profiling market are F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, OncoDNA, Strata Oncology Inc., RareCyte Inc., Inivata Limited, Cepheid.
North America was the largest region in cancer and tumor profiling market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer tumor profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cancer tumor profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the cancer tumor profiling market by increasing costs of imported sequencing platforms, reagents, immunohistochemistry systems, and bioinformatics tools required for comprehensive tumor analysis. North America and Europe are most affected due to reliance on imported diagnostic technologies, while Asia-Pacific faces cost pressures in scaling profiling services. These tariffs are increasing operational costs for laboratories and healthcare providers. However, they are also supporting domestic diagnostic manufacturing, regional technology development, and long-term resilience in oncology profiling supply chains.
The cancer tumor profiling market research report is one of a series of new reports that provides cancer tumor profiling market statistics, including cancer tumor profiling industry global market size, regional shares, competitors with a cancer tumor profiling market share, detailed cancer tumor profiling market segments, market trends and opportunities, and any further data you may need to thrive in the cancer tumor profiling industry. This cancer tumor profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cancer tumor profiling is a laboratory test that analyzes a sample of tumor tissue for specific genes, gene mutations (alterations), proteins, or other biomarkers. Tumor profiling can assist in treatment planning as well as in predicting whether cancer may recur or spread to other areas of the body.
The main types of cancer and tumor profiling include lung cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, ovarian cancer, stomach cancer, pancreatic cancer, thyroid cancer, and other cancer types. The various technologies comprise next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), microarrays, and others, and involve different processes such as genomics, proteomics, epigenetics, metabolomics, and more. It is utilized in multiple applications, including personalized medicine, diagnostics, biomarker discovery, prognostics, and research purposes.
The cancer tumor profiling market includes revenues earned by entities by sanger sequencing, pyro sequencing (PyroSeq), chromogenic/ fluorescence in situ hybridization (CISH/FISH) and fragment analysis (FA/Frag. Analysis). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The cancer tumor profiling market size is expected to see rapid growth in the next few years. It will grow to $28.27 billion in 2030 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to increasing demand for precision oncology decision-making, expansion of personalized cancer therapies, growing investments in translational research, rising adoption of advanced sequencing technologies, increasing focus on predictive oncology diagnostics. Major trends in the forecast period include increasing use of multi-omics tumor profiling, rising adoption of targeted sequencing panels, growing integration of AI-driven biomarker analysis, expansion of personalized treatment planning, enhanced focus on prognostic profiling.
The rising incidences of cancer worldwide are expected to drive the growth of the cancer and tumor profiling market in the coming years. Cancer is a disease in which certain cells in the body grow uncontrollably and spread to other parts of the body. As cancer cases increase, the demand for cancer tumor profiling also rises, as it helps doctors assess the severity of the disease. For example, in 2024, the American Cancer Society, a US-based professional organization, reported 2 million new cancer cases in the country, up from 1.9 million new cases in 2023. Thus, the growing number of cancer cases globally fuels the expansion of the cancer and tumor profiling market.
The rising incidence of stomach cancer is expected to drive the growth of the cancer and tumor profiling market in the coming years. Stomach cancer involves the uncontrolled growth and proliferation of malignant cells in the stomach lining. While gastrointestinal stromal tumors (GISTs) can also develop in the stomach, they are different from stomach cancer. When two distinct tumors merge, patients with GISTs have been observed to have a higher risk of developing additional cancers, including small bowel adenocarcinoma. Cancer and tumor profiling provides insights into cancer development in the stomach and helps guide more effective treatment. For example, according to Cancer Research UK, an independent cancer research organization, the incidence of stomach cancer in the UK is expected to decrease by 12% between 2023-2025 and 2038-2040, averaging 8 cases per 100,000 people per year. Consequently, the increasing incidence of stomach cancer is fueling the growth of the cancer and tumor profiling market.
In February 2024, AbbVie Inc. acquired US-based pharmaceutical company ImmunoGen, Inc. for an undisclosed amount. Through this acquisition, AbbVie Inc. intends to enhance its research and development capabilities, expand its product portfolio, and accelerate growth in key therapeutic areas. ImmunoGen, Inc. is a US-based biotechnology firm specializing in the development of antibody-drug conjugate therapeutics for cancer treatment.
Major companies operating in the cancer tumor profiling market are F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, OncoDNA, Strata Oncology Inc., RareCyte Inc., Inivata Limited, Cepheid.
North America was the largest region in cancer and tumor profiling market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer tumor profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cancer tumor profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the cancer tumor profiling market by increasing costs of imported sequencing platforms, reagents, immunohistochemistry systems, and bioinformatics tools required for comprehensive tumor analysis. North America and Europe are most affected due to reliance on imported diagnostic technologies, while Asia-Pacific faces cost pressures in scaling profiling services. These tariffs are increasing operational costs for laboratories and healthcare providers. However, they are also supporting domestic diagnostic manufacturing, regional technology development, and long-term resilience in oncology profiling supply chains.
The cancer tumor profiling market research report is one of a series of new reports that provides cancer tumor profiling market statistics, including cancer tumor profiling industry global market size, regional shares, competitors with a cancer tumor profiling market share, detailed cancer tumor profiling market segments, market trends and opportunities, and any further data you may need to thrive in the cancer tumor profiling industry. This cancer tumor profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cancer tumor profiling is a laboratory test that analyzes a sample of tumor tissue for specific genes, gene mutations (alterations), proteins, or other biomarkers. Tumor profiling can assist in treatment planning as well as in predicting whether cancer may recur or spread to other areas of the body.
The main types of cancer and tumor profiling include lung cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, ovarian cancer, stomach cancer, pancreatic cancer, thyroid cancer, and other cancer types. The various technologies comprise next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), microarrays, and others, and involve different processes such as genomics, proteomics, epigenetics, metabolomics, and more. It is utilized in multiple applications, including personalized medicine, diagnostics, biomarker discovery, prognostics, and research purposes.
The cancer tumor profiling market includes revenues earned by entities by sanger sequencing, pyro sequencing (PyroSeq), chromogenic/ fluorescence in situ hybridization (CISH/FISH) and fragment analysis (FA/Frag. Analysis). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Cancer Tumor Profiling Market Characteristics
3. Cancer Tumor Profiling Market Supply Chain Analysis
4. Global Cancer Tumor Profiling Market Trends and Strategies
5. Cancer Tumor Profiling Market Analysis of End Use Industries
7. Global Cancer Tumor Profiling Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Cancer Tumor Profiling Total Addressable Market (TAM) Analysis for the Market
9. Cancer Tumor Profiling Market Segmentation
10. Cancer Tumor Profiling Market Regional and Country Analysis
11. Asia-Pacific Cancer Tumor Profiling Market
12. China Cancer Tumor Profiling Market
13. India Cancer Tumor Profiling Market
14. Japan Cancer Tumor Profiling Market
15. Australia Cancer Tumor Profiling Market
16. Indonesia Cancer Tumor Profiling Market
17. South Korea Cancer Tumor Profiling Market
18. Taiwan Cancer Tumor Profiling Market
19. South East Asia Cancer Tumor Profiling Market
20. Western Europe Cancer Tumor Profiling Market
21. UK Cancer Tumor Profiling Market
22. Germany Cancer Tumor Profiling Market
23. France Cancer Tumor Profiling Market
24. Italy Cancer Tumor Profiling Market
25. Spain Cancer Tumor Profiling Market
26. Eastern Europe Cancer Tumor Profiling Market
27. Russia Cancer Tumor Profiling Market
28. North America Cancer Tumor Profiling Market
29. USA Cancer Tumor Profiling Market
30. Canada Cancer Tumor Profiling Market
31. South America Cancer Tumor Profiling Market
32. Brazil Cancer Tumor Profiling Market
33. Middle East Cancer Tumor Profiling Market
34. Africa Cancer Tumor Profiling Market
36. Cancer Tumor Profiling Market Competitive Landscape and Company Profiles
37. Cancer Tumor Profiling Market Other Major and Innovative Companies
40. Cancer Tumor Profiling Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Cancer Tumor Profiling Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses cancer tumor profiling market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cancer tumor profiling? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cancer tumor profiling market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Cancer Type: Lung Cancer; Breast Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Ovarian Cancer; Stomach Cancer; Pancreatic Cancer; Thyroid Cancer; Other Cancer Types2) By Technology: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); Immunohistochemistry (IHC); In Situ Hybridization (ISH); Microarray; Other Technologies
3) By Process Type: Genomics; Proteomics; Epigenetics; Other Types
4) By Application: Personalized Medicine; Diagnostics; Biomarker Discovery; Prognostics; Research Applications
Subsegments:
1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC); Small Cell Lung Cancer (SCLC)2) By Breast Cancer: Hormone Receptor-Positive; Triple-Negative Breast Cancer; HER2-Positive Breast Cancer
3) By Colorectal Cancer: Colon Cancer; Rectal Cancer
4) By Prostate Cancer: Localized Prostate Cancer; Advanced Prostate Cancer
5) By Melanoma: Cutaneous Melanoma; Non-Cutaneous Melanoma
6) By Ovarian Cancer: Epithelial Ovarian Cancer; Non-Epithelial Ovarian Cancer
7) By Stomach Cancer: Gastric Adenocarcinoma; Gastrointestinal Stromal Tumors (GISTs)
8) By Pancreatic Cancer: Exocrine Pancreatic Cancer; Neuroendocrine Tumors
9) By Thyroid Cancer: Papillary Thyroid Cancer; Follicular Thyroid Cancer; Medullary Thyroid Cancer
10) By Other Cancer Types: Kidney Cancer; Bladder Cancer; Liver Cancer; Esophageal Cancer
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Caris Life Sciences; Thermo Fisher Scientific Inc.; Illumina Inc.; Qiagen; HTG Molecular Diagnostics Inc.; NanoString Technologies Inc.; NeoGenomics Laboratories Inc.; Lucence Health Inc.; ACT Genomics Co. LTD; Strand Life Sciences; Exact Sciences Corporation; Guardant Health; Foundation Medicine Inc.; Agilent Technologies Inc.; Myriad Genetics Inc.; Personal Genome Diagnostics Inc.; Tempus Labs Inc.; ArcherDX Inc.; Natera Inc.; Bio-Rad Laboratories Inc.; Genetron Health; NantHealth Inc.; Resolution Bioscience; OncoDNA; Strata Oncology Inc.; RareCyte Inc.; Inivata Limited; Cepheid
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Cancer Tumor Profiling market report include:- F. Hoffmann-La Roche Ltd.
- Caris Life Sciences
- Thermo Fisher Scientific Inc.
- Illumina Inc.
- Qiagen
- HTG Molecular Diagnostics Inc.
- NanoString Technologies Inc.
- NeoGenomics Laboratories Inc.
- Lucence Health Inc.
- ACT Genomics Co. LTD
- Strand Life Sciences
- Exact Sciences Corporation
- Guardant Health
- Foundation Medicine Inc.
- Agilent Technologies Inc.
- Myriad Genetics Inc.
- Personal Genome Diagnostics Inc.
- Tempus Labs Inc.
- ArcherDX Inc.
- Natera Inc.
- Bio-Rad Laboratories Inc.
- Genetron Health
- NantHealth Inc.
- Resolution Bioscience
- OncoDNA
- Strata Oncology Inc.
- RareCyte Inc.
- Inivata Limited
- Cepheid
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 17.1 Billion |
| Forecasted Market Value ( USD | $ 28.27 Billion |
| Compound Annual Growth Rate | 13.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
